Agenus INC (AGEN) — SEC Filings

Overview

Agenus INC (AGEN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 21, 2026: On April 17, 2026, Armen Garo, a reporting person for AGENUS INC, acquired 10,000 shares of common stock through the exercise of stock options. The transaction was reported on a Form 4 filing accepted by the SEC on April 21, 2026.

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 1 bearish, 41 neutral, 2 mixed. The dominant filing sentiment for Agenus INC is neutral.

Filing Type Overview

Agenus INC (AGEN) has filed 1 4, 19 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 8 SC 13G/A, 3 SC 13G, 1 8-K/A, 1 DEFA14A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (44)

• AGENUS INC Insider Acquires 10,000 Shares — 4 · Apr 21, 2026 Risk: low
  On April 17, 2026, Armen Garo, a reporting person for AGENUS INC, acquired 10,000 shares of common stock through the exercise of stock options. The transaction
• AGENUS Files 8-K for Undisclosed 'Other Event' on March 24, 2026 — 8-K · Mar 26, 2026
  AGENUS INC filed an 8-K on March 26, 2026, reporting an "Other Event" that occurred on March 24, 2026. While the specific details of the event are not disclosed
• Agenus Swings to Profit on MiNK Deconsolidation, Cash Remains Tight — 10-Q · Nov 10, 2025 Risk: high
  Agenus Inc. reported a significant turnaround in net income, achieving $7.5 million for the nine months ended September 30, 2025, compared to a net loss of $185
• AGENUS INC Enters Material Definitive Agreement — 8-K · Oct 9, 2025 Risk: medium
  On October 8, 2025, AGENUS INC. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as ANTIGENICS
• AGENUS INC. Files 8-K Report — 8-K · Sep 23, 2025 Risk: low
  On September 17, 2025, AGENUS INC. filed an 8-K report detailing an event under 'Other Events'. The company, formerly known as ANTIGENICS INC /DE/, is incorpora
• AGENUS Revenue Jumps 62% on R&D Boost, Net Loss Narrows — 10-Q · Aug 11, 2025 Risk: high
  AGENUS INC reported a significant increase in total revenue for the six months ended June 30, 2025, reaching $60.0 million, up from $37.0 million in the prior y
• AGENUS INC. Files 8-K on Security Holder Vote Matters — 8-K · Jun 20, 2025 Risk: low
  On June 17, 2025, AGENUS INC. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing, made on June 20, 2025, pert
• AGENUS INC Files 8-K for Material Definitive Agreement — 8-K · Jun 4, 2025 Risk: medium
  On June 3, 2025, AGENUS INC. (formerly ANTIGENICS INC /DE/) entered into a material definitive agreement. The company, incorporated in Delaware with its princip
• Agenus Inc. Q1 2025 Update: Ligand Deal & Sales Agreements — 10-Q · May 12, 2025 Risk: medium
  Agenus Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's filing indicates various financial activities and agreem
• Agenus Inc. Executive Compensation Details Revealed — DEF 14A · Apr 30, 2025 Risk: low
  Agenus Inc. filed a DEF 14A on April 30, 2025, detailing executive compensation. The filing includes information on equity awards granted to its "PeoMember" (li
• Agenus Inc. Files 2024 10-K — 10-K · Mar 17, 2025 Risk: medium
  Agenus Inc. filed its 2024 10-K on March 17, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Antigenics Inc. /DE/, i
• AGENUS INC. Files 8-K on Financials — 8-K · Mar 11, 2025 Risk: low
  On March 11, 2025, AGENUS INC. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financ
• AGENUS INC. Files 8-K: Material Agreement, Equity Sales — 8-K · Feb 26, 2025 Risk: medium
  On February 20, 2025, AGENUS INC. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unregistere
• Agenus Inc. Terminates Material Definitive Agreement — 8-K · Feb 10, 2025 Risk: medium
  Agenus Inc. reported on February 4, 2025, the termination of a material definitive agreement. The company, formerly known as Antigenics Inc. /DE/, is incorporat
• AGENUS INC. Files 8-K on Exit Costs and Financials — 8-K · Dec 5, 2024 Risk: medium
  On December 5, 2024, AGENUS INC. filed an 8-K report detailing costs associated with exit or disposal activities. The filing also includes financial statements
• AGENUS INC. Files 8-K: Material Agreement, Financial Obligations, Equity Sales — 8-K · Nov 27, 2024 Risk: medium
  On November 26, 2024, AGENUS INC. entered into a material definitive agreement. The company also reported the creation of a direct financial obligation and unre
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Agenus Inc. Files Q3 2024 10-Q with Financial Details — 10-Q · Nov 12, 2024 Risk: medium
  Agenus Inc. reported its third-quarter results for the period ending September 30, 2024. The company's filing details various financial components, including co
• SC 13G Filing — SC 13G · Nov 8, 2024
• Agenus Inc. Amends 8-K Filing on Officer and Director Changes — 8-K/A · Nov 8, 2024 Risk: low
  Agenus Inc. filed an 8-K/A on November 8, 2024, to amend a previous filing regarding events that occurred on August 8, 2024. The amendment pertains to the depar
• Agenus Inc. Appoints New CMO, Elects Director — 8-K · Nov 5, 2024 Risk: medium
  On October 30, 2024, AGENUS INC. announced the appointment of Dr. David E. Johnson as Chief Medical Officer and the election of Ms. Sarah Chen to its Board of D
• SC 13G Filing — SC 13G · Oct 22, 2024
• Agenus Inc. Reports Director Changes and Financial Updates — 8-K · Aug 8, 2024 Risk: medium
  On August 7, 2024, AGENUS INC. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Robert L. S. Van der Laan a
• Agenus Inc. Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Agenus Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter. Key fin
• AGENUS INC Terminates Material Definitive Agreement — 8-K · Aug 2, 2024 Risk: medium
  On July 30, 2024, AGENUS INC. reported the termination of a material definitive agreement. The filing does not specify the other party involved in the agreement
• Agenus Inc. Appoints New Chief Medical and Scientific Officers — 8-K · Jun 17, 2024 Risk: medium
  On June 11, 2024, AGENUS INC. announced the appointment of Dr. David E. Johnson as Chief Medical Officer and Dr. Robert J. T. Miller as Chief Scientific Officer
• AGENUS INC. Files 8-K on Security Holder Vote Matters — 8-K · Jun 14, 2024 Risk: low
  On June 11, 2024, AGENUS INC. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as ANTIGENICS INC
• SC 13G/A Filing — SC 13G/A · Jun 10, 2024
• AGENUS INC Completes Asset Acquisition/Disposition — 8-K · May 30, 2024 Risk: medium
  On May 29, 2024, AGENUS INC. (formerly ANTIGENICS INC /DE/) reported the completion of an acquisition or disposition of assets. The company, incorporated in Del
• Agenus Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: medium
  AGENUS INC (AGEN) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Agenus Inc. filed a 10-Q report for the quarterly period ended March 31, 2024. Th
• AGENUS INC Files DEF 14A with Executive Compensation Details — DEF 14A · Apr 26, 2024 Risk: low
  AGENUS INC (AGEN) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Filing type is DEF 14A, filed on 2024-04-26, reporting period ending 2024-06
• Agenus Inc. Holds Annual Meeting, Elects Directors — 8-K · Apr 5, 2024 Risk: low
  On April 3, 2024, Agenus Inc. filed an 8-K report detailing several key events. The company announced the results of its 2024 Annual Meeting of Stockholders, wh
• AGENUS INC. 2023 Annual Report (10-K) — 10-K · Mar 14, 2024 Risk: medium
  AGENUS INC (AGEN) filed a Annual Report (10-K) with the SEC on March 14, 2024. Agenus Inc. filed its 2023 10-K report on March 14, 2024. The company's fiscal ye
• Agenus Amends Proxy for April 3 Special Stockholder Meeting — DEFA14A · Feb 29, 2024 Risk: low
  Agenus Inc. filed Amendment No. 1 to its proxy statement on February 29, 2024, for a Special Meeting of Stockholders scheduled for April 3, 2024. The filing, a
• Agenus Inc. Announces Special Meeting for Stockholder Vote on Reverse Stock Split — DEF 14A · Feb 26, 2024 Risk:
  AGENUS INC (AGEN) filed a Proxy Statement (DEF 14A) with the SEC on February 26, 2024. Agenus Inc. is holding a Special Meeting of Stockholders on April 3, 2024
• SC 13G Filing — SC 13G · Feb 21, 2024
• AGENUS INC. Files 8-K for Regulation FD and Financial Exhibits — 8-K · Feb 15, 2024 Risk: low
  AGENUS INC. filed an 8-K on February 15, 2024, to report an event under Regulation FD Disclosure and to file Financial Statements and Exhibits. This procedural
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Artal International Affiliates Maintain Significant Agenus Stake — SC 13G/A · Feb 9, 2024 Risk: low
  Artal International S.C.A. and its affiliated entities, including ARTAL GROUP S.A. and INVUS PUBLIC EQUITIES, L.P., filed an amended Schedule 13G/A on February
• AGENUS Files Routine 8-K on Jan 30; Confirms Nasdaq Listing — 8-K · Jan 31, 2024
  AGENUS INC. filed an 8-K on January 31, 2024, reporting an 'Other Event' that occurred on January 30, 2024. This filing is a routine update to the SEC, confirmi
• BlackRock Amends AGENUS INC Stake, Maintains Institutional Holding — SC 13G/A · Jan 25, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, indicating a change in its ownership of AGENUS INC common stock as of December 31, 2023. This fili
• State Street Exits Agenus Inc. Stake as of Dec 31, 2023 — SC 13G/A · Jan 22, 2024
  State Street Corporation, a major financial institution, filed an amended Schedule 13G on January 22, 2024, indicating its ownership of Agenus Inc. common stock

Related Companies

INKT

Frequently Asked Questions